STOKE THERAPEUTICS INC (STOK:NASDAQ)
$35.9 0.29 (0.8144%)
Analysed STOKE THERAPEUTICS INC (STOK:NASDAQ) News Sources
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
16-04-2026
yahoo.com
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
14-04-2026
yahoo.com
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
08-04-2026
yahoo.com
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
07-04-2026
yahoo.com
Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus
06-04-2026
yahoo.com
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
01-04-2026
biopharmadive.com
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
28-03-2026
fool.com
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
24-03-2026
fool.com
Biogen Rare Disease Data And Valuation Discount Draw Investor Attention
12-03-2026
yahoo.com
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
12-03-2026
yahoo.com
What is the current price of STOKE THERAPEUTICS INC (STOK:NASDAQ)?
The current price of STOKE THERAPEUTICS INC (STOK:NASDAQ) is $35.9.
STOKE THERAPEUTICS INC (STOK:NASDAQ) absolute price change since previous trading day?
The absolute price change of STOKE THERAPEUTICS INC (STOK:NASDAQ) since the previous trading day is $0.29.
STOKE THERAPEUTICS INC (STOK:NASDAQ) percentage price change since previous trading day?
The percentage price change of STOKE THERAPEUTICS INC (STOK:NASDAQ) since the previous trading day is 0.8144%.
What is the most recent average sentiment score for STOKE THERAPEUTICS INC (STOK:NASDAQ)?
The most recent average sentiment score for STOKE THERAPEUTICS INC (STOK:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for STOKE THERAPEUTICS INC (STOK:NASDAQ)?
The most recent sentiment for STOKE THERAPEUTICS INC (STOK:NASDAQ) is .
SEC-8K** Filing Available For STOKE THERAPEUTICS INC (STOK:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.